Home » Stocks » GNFT

Genfit S.A. (GNFT)

Stock Price: $3.80 USD 0.05 (1.33%)
Updated Jul 23, 2021 4:00 PM EDT - Market closed
Market Cap 178.71M
Revenue (ttm) 9.46M
Net Income (ttm) -123.44M
Shares Out 45.67M
EPS (ttm) -3.07
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 23
Last Price $3.80
Previous Close $3.75
Change ($) 0.05
Change (%) 1.33%
Day's Open 3.87
Day's Range 3.61 - 3.90
Day's Volume 35,072
52-Week Range 3.50 - 7.19

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Lille, France; Cambridge , M A ; J uly 09 , 202 1 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver disea...

2 weeks ago - GlobeNewsWire

L ille (France) ; C ambridge ( M assachusetts, United States) — June 30 , 202 1 — GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients ...

3 weeks ago - GlobeNewsWire

Lille, France; Cambridge, M A ; June 24 , 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases...

1 month ago - GlobeNewsWire

Lille, France; Cambridge, M A ; June 2 3 , 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver disease...

1 month ago - GlobeNewsWire

Lille, France; Cambridge , M A ; J une 15 , 202 1 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver disea...

1 month ago - GlobeNewsWire

Lille, France; Cambridge, M A ; Ma y 27 , 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases...

1 month ago - GlobeNewsWire

(Unaudited financial information under IFRS)

2 months ago - GlobeNewsWire

Lille, France; Cambridge, M A ; May 11 , 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases,...

2 months ago - GlobeNewsWire

Lille, France; Cambridge, M A ; May 10, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases (...

2 months ago - GlobeNewsWire

Lille, France; Cambridge, M A ; April 23 , 202 1 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseas...

3 months ago - GlobeNewsWire

Lille, France; Cambridge , M A ; April 2 2 , 202 1 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver dise...

3 months ago - GlobeNewsWire

GENFIT Reports Full-Year 2020 Financial Results and Provides Corporate Update

3 months ago - GlobeNewsWire

Lille, France; Cambridge, MA; March 04, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, ...

4 months ago - GlobeNewsWire

Lille, France; Cambridge, MA; February 26, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver disease...

4 months ago - GlobeNewsWire

Lille, France; Cambridge, MA; February 22, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver disease...

5 months ago - GlobeNewsWire

Lille, France; Cambridge, MA; February 10, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver disease...

5 months ago - GlobeNewsWire

Investors applauded the company's latest clinical results.

5 months ago - The Motley Fool

Genfit SA (NASDAQ: GNFT) shares shot up 150% in the after-hours trading today. What Happened: The France-based late-stage biopharmaceutical company said in the after-hours Tuesday that positive results ...

5 months ago - Benzinga

Lille, France; Cambridge, MA; February 09, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver disease...

5 months ago - GlobeNewsWire

Lille, France; Cambridge, MA; January 28, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases...

5 months ago - GlobeNewsWire

Lille, France; Cambridge, MA; January 27, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases...

5 months ago - GlobeNewsWire

LOS ANGELES--(BUSINESS WIRE)---- $GNFT #GNFT--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Genfit SA

6 months ago - Business Wire

Lille, France; Cambridge, MA; January 13, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases...

6 months ago - GlobeNewsWire

Lille, France; Cambridge, MA; January 11, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases...

6 months ago - GlobeNewsWire

Lille, France; Cambridge, MA; January 8, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases ...

6 months ago - GlobeNewsWire

Lille, France; Cambridge, MA; January 6, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases,...

6 months ago - GlobeNewsWire

SAN DIEGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $GNFT #ClassAction--Shareholder rights law firm Robbins LLP announces that a purchaser of Genfit SA American Depository Shares (NASDAQ: GNFT) filed a cl...

7 months ago - Business Wire

LOS ANGELES--(BUSINESS WIRE)---- $GNFT #classaction--The Law Offices of Frank R. Cruz Announces Investigation of Genfit S.A. (GNFT) on Behalf of Investors

7 months ago - Business Wire

BENSALEM, Pa.--(BUSINESS WIRE)---- $GNFT #CLASSACTION--INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Genfit S.A. (GNFT) on Behalf of Investors

7 months ago - Business Wire

LOS ANGELES--(BUSINESS WIRE)---- $GNFT #CLASSACTION--Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Genfit S.A. (GNFT) on Behalf of Investors

7 months ago - Business Wire

Lille (France), Cambridge (Massachusetts, United States), December 7, 2020 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with ...

7 months ago - GlobeNewsWire

Lille (France), Cambridge (Massachusetts, United States), November 30, 2020 – GENFIT (Nasdaq and Euronext: GNFT) a late-stage biopharmaceutical company dedicated to improving the lives of patients with ...

7 months ago - GlobeNewsWire

Lille (France), Cambridge (Massachusetts, United States), November 23, 2020 – GENFIT (Nasdaq and Euronext: GNFT) a late-stage biopharmaceutical company dedicated to improving the lives of patients with ...

8 months ago - GlobeNewsWire

Lille (France), Cambridge (Massachusetts, United States), November 16, 2020 – GENFIT (Nasdaq and Euronext: GNFT a late-stage biopharmaceutical company dedicated to improving the lives of patients with m...

8 months ago - GlobeNewsWire

                   

8 months ago - GlobeNewsWire

GENFIT SA (GNFT) CEO Pascal Prigent on Q2 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

Genfit SA (NASDAQ: GNFT) shot up on Monday after the company announced an agreement with Lab Corporation of America Holdings (NYSE: LH).

Other stocks mentioned: LH
9 months ago - 24/7 Wall Street

Lille, France; Cambridge, M.A.; September 24, 2020 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver dise...

10 months ago - GlobeNewsWire

Lille, France; Cambridge, M.A.; September 22, 2020 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver dise...

10 months ago - GlobeNewsWire

Lille, France; Cambridge, M.A.; August 26, 2020 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver disease...

10 months ago - GlobeNewsWire

Lille (France), Cambridge (Massachusetts, United States), August 05, 2020 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with m...

11 months ago - GlobeNewsWire

       

1 year ago - GlobeNewsWire

Genfit: Beaten Down But Not Dead

1 year ago - Seeking Alpha

Genfit (GNFT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

1 year ago - Zacks Investment Research

Genfit’s (NASDAQ:GNFT) loss may be a gain for other companies developing a treatment for one of the most rapidly growing health problems around the world, particularly Intercept Pharmaceuticals Inc.

1 year ago - GuruFocus

Non-alcoholic steatohepatitis biotechs are increasingly finding it difficult to make headway, and the lack of any approved therapy despite a slew of research is a testament to the challenge.

Other stocks mentioned: CBAY
1 year ago - Benzinga

One of the company's pipeline candidates flopped in a late-stage clinical trial.

1 year ago - The Motley Fool

Genfit stock lost half its value late Monday after the biotech company's promising hepatitis treatment failed in a Phase 3 test. The results are a boon for rival Intercept Pharmaceuticals.

1 year ago - Investors Business Daily

About GNFT

Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test. Genfit S.A. was... [Read more...]

Industry
Biotechnology
IPO Date
Mar 27, 2019
CEO
Pascal Prigent
Employees
130
Stock Exchange
NASDAQ
Ticker Symbol
GNFT
Full Company Profile

Financial Performance

In 2020, Genfit's revenue was 7.76 million, a decrease of -81.06% compared to the previous year's 40.96 million. Losses were -101.22 million, 55.4% more than in 2019.

Financial numbers in millions EUR.
Financial Statements